



Molecular Mechanisms and Therapeutic Resistance in Cancer: Insights from Transcriptional Regulation and Immune Modulation

Guest Editor:

Dr. Hyunmin Kim

Department of Genetics and
Genome Sciences, CASE School
of Medicine, Cleveland, OH
44106, USA

Deadline for manuscript
submissions:

closed (20 November 2024)

Message from the Guest Editor

Despite significant advances in cancer diagnosis and treatment, therapeutic resistance remains a significant obstacle to effective cancer management.

This Special Issue aims to delve into the intricate relationship between transcriptional dysregulation in immune and other systems and its role in therapeutic resistance in cancer. Topics of interest include, but are not limited to, exploring epigenomic mechanisms, translational regulators, cell-to-cell communication, cancer microenvironmental evolution, and spatio-single-cell level interpretation. These investigations will shed light on the core factors operating at the transcriptional layer and their implications for therapeutic strategies in combating cancer resistance. Contributors to this Special Issue are encouraged to utilize state-of-the-art genomic technologies and computational methodologies to identify novel therapeutic targets and develop personalized cancer therapies.

Join our Special Issue on overcoming transcriptional dysregulation and therapeutic resistance in cancer through innovative solutions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)